Merakris Therapeutics
Merakris Therapeutics Announces the Commercial Launch of Dermacyte® Matrix and CMS Assignment of an HCPCS Code for Use as a Skin Graft Substitute
This is another milestone for Merakris Therapeutics that the largest healthcare payer, CMS, has recognized Dermacyte Matrix with a unique reimbursement code.